Warning: The NCBI web site requires JavaScript to function. more...
The utility of conventional and molecular pathology in managing breast cancer.
Allred DC.
Breast Cancer Res. 2008;10 Suppl 4:S4. Epub 2008 Dec 18. No abstract available.
Related citations
The use of microarray technology in the management of breast cancer.
Pusztai L.
Clin Adv Hematol Oncol. 2007 Mar;5(3):193-4, 197. No abstract available.
Gene-expression profiling in breast cancer.
Jenssen TK, Hovig E.
Lancet. 2005 Feb 19-25;365(9460):634-5. No abstract available.
Predicting the future of breast cancer.
Borg A, Fernö M, Peterson C.
Nat Med. 2003 Jan;9(1):16-8. No abstract available.
Molecular subtyping of breast cancer: ready to use?
de Ronde J, Wessels L, Wesseling J.
Lancet Oncol. 2010 Apr;11(4):306-7. No abstract available.
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S.
Lancet Oncol. 2009 Apr;10(4):381-90. Epub 2009 Feb 25.
Breast cancer genomics: real-time use.
Bertucci F, Birnbaum D.
Lancet Oncol. 2007 Dec;8(12):1045-7. No abstract available.
Prediction of cancer outcome with microarrays.
Lee AH.
Lancet. 2005 May 14-20;365(9472):1685; author reply 1686. No abstract available.
The non-invasive diagnosis of lymph-node status based on gene expression profiles of primary breast cancer tumors.
Okimoto GS.
Hawaii Med J. 2007 Jan;66(1):17-9. No abstract available.
[Gene expression analysis using cDNA array in infiltrating ductal carcinoma].
Shindo M.
Hokkaido Igaku Zasshi. 2005 Jan;80(1):41-52. Japanese. No abstract available.
Genetic profiling of breast cancer: from molecular portraits to clinical utility.
Børresen-Dale AL.
Int J Biol Markers. 2003 Jan-Mar;18(1):54-6. Review. No abstract available.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR.
PLoS One. 2009 Jul 3;4(7):e6146.
Molecular subtypes in breast cancer evaluation and management: divide and conquer.
Peppercorn J, Perou CM, Carey LA.
Cancer Invest. 2008 Feb;26(1):1-10. Review. No abstract available.
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS.
Adv Anat Pathol. 2009 Jul;16(4):204-15. Review.
[Study of gene expression profiling in breast cancer by DNA microarray].
Feng YM, Li XQ, Sun BC, Zhang L, Hao XS.
Zhonghua Bing Li Xue Za Zhi. 2006 Jun;35(6):361-2. Chinese. No abstract available.
The molecular outlook.
Caldas C, Aparicio SA.
Nature. 2002 Jan 31;415(6871):484-5. No abstract available.
[Histopathologic diagnosis of luminal and basal type breast cancer].
Sarcević B.
Acta Med Croatica. 2008 Oct;62(4):427-30. Croatian.
Treatment tailoring based on molecular characterizations.
Dinh P, Sotiriou C.
Ann Oncol. 2008 Sep;19 Suppl 7:vii46-50. No abstract available.
Lost in translation--prognostic signatures for breast cancer.
Nat Clin Pract Oncol. 2008 Jul;5(7):363. No abstract available.
New molecular classifications of breast cancer.
Cianfrocca M, Gradishar W.
CA Cancer J Clin. 2009 Sep-Oct;59(5):303-13. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on